drugset / Trial / NCT06727617
Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors
RandomizedParallel-groupOpen-labelTreatment
Summary
A Phase II Study of Serplulimab Plus Chemoradiotherapy as Adjuvant Treatment for Postoperative Cervical Cancer with Multiple Risk Factors
Timeline
- Start
- 2024-11-19
- Primary completion
- 2025-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Serplulimab | Monoclonal antibody | 300 mg | Intravenous |
| Background | Cisplatin | Other / unclassified | 30 mg/m2 | Intravenous |
| Background | Cisplatin | Other / unclassified | 40 mg/m2 | Intravenous |
| Background | Cisplatin | Other / unclassified | 60 mg/m2 | Intravenous |
| Background | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Background | Paclitaxel | Small molecule | 135 mg/m2 | Intravenous |
| Background | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |